Multicentre, Randomized, Prospective Trial Evaluating the Efficacy and Safety of Infliximab to Tocilizumab in Refractory or Relapsing Takayasu Arteritis

NCT04564001 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Takayasu Arteritis

Interventions

DRUG: Infliximab
DRUG: Tocilizumab

Sponsor

Assistance Publique - Hôpitaux de Paris